JP2022540890A5 - - Google Patents
Info
- Publication number
- JP2022540890A5 JP2022540890A5 JP2022502302A JP2022502302A JP2022540890A5 JP 2022540890 A5 JP2022540890 A5 JP 2022540890A5 JP 2022502302 A JP2022502302 A JP 2022502302A JP 2022502302 A JP2022502302 A JP 2022502302A JP 2022540890 A5 JP2022540890 A5 JP 2022540890A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- independently
- pharmaceutically acceptable
- acceptable salt
- compound according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962874533P | 2019-07-16 | 2019-07-16 | |
| US62/874,533 | 2019-07-16 | ||
| US201962927974P | 2019-10-30 | 2019-10-30 | |
| US62/927,974 | 2019-10-30 | ||
| US202062987653P | 2020-03-10 | 2020-03-10 | |
| US62/987,653 | 2020-03-10 | ||
| US202063049927P | 2020-07-09 | 2020-07-09 | |
| US63/049,927 | 2020-07-09 | ||
| PCT/US2020/042183 WO2021011689A1 (en) | 2019-07-16 | 2020-07-15 | Cd73 inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022540890A JP2022540890A (ja) | 2022-09-20 |
| JP2022540890A5 true JP2022540890A5 (enExample) | 2023-05-12 |
| JP7557522B2 JP7557522B2 (ja) | 2024-09-27 |
Family
ID=74209960
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022502302A Active JP7557522B2 (ja) | 2019-07-16 | 2020-07-15 | Ｃｄ７３阻害剤 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US12544391B2 (enExample) |
| EP (1) | EP3999517A4 (enExample) |
| JP (1) | JP7557522B2 (enExample) |
| WO (1) | WO2021011689A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018208980A1 (en) | 2017-05-10 | 2018-11-15 | Oric Pharmaceuticals, Inc. | Cd73 inhibitors |
| WO2019090111A1 (en) | 2017-11-03 | 2019-05-09 | Oric Pharmaceuticals, Inc. | Cd73 inhibitors |
| CN112423764A (zh) | 2018-04-30 | 2021-02-26 | 欧瑞克制药公司 | Cd73抑制剂 |
| EP3999517A4 (en) | 2019-07-16 | 2023-07-12 | Oric Pharmaceuticals, Inc. | CD73 INHIBITORS |
| IL292570B2 (en) | 2019-10-30 | 2024-04-01 | Oric Pharmaceuticals Inc | Cd73 inhibitors |
| EP4504341A1 (en) | 2022-04-08 | 2025-02-12 | Shy Therapeutics LLC | Compounds that interact with ras superfamily proteins for treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease |
| KR20250004779A (ko) | 2022-04-13 | 2025-01-08 | 길리애드 사이언시즈, 인코포레이티드 | Trop-2 발현 암을 치료하기 위한 병용 요법 |
| WO2025096605A1 (en) * | 2023-10-31 | 2025-05-08 | Oric Pharmaceuticals, Inc. | Cd73 inhibitor and anti-cd38 agent combination therapy |
| WO2025137640A1 (en) | 2023-12-22 | 2025-06-26 | Gilead Sciences, Inc. | Azaspiro wrn inhibitors |
| CN118359622B (zh) * | 2024-04-16 | 2025-08-26 | 上海陶术生物科技股份有限公司 | 加利司伟中间体的制备方法 |
| WO2025233264A1 (en) | 2024-05-07 | 2025-11-13 | Innate Pharma | Use of cd73 blocking agents in combination with anti-cd20 x cd3 t cell engagers |
| CN119552122B (zh) * | 2025-01-27 | 2025-05-09 | 北京悦康科创医药科技股份有限公司 | 5'-磷酸酯修饰核苷及其制备方法与应用 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0477454A1 (en) | 1990-09-28 | 1992-04-01 | Merrell Dow Pharmaceuticals Inc. | Novel phosphonate derivatives of certain nucleosides |
| AU2002232660A1 (en) | 2000-12-15 | 2002-06-24 | Pharmasset Ltd. | Antiviral agents for treatment of flaviviridae infections |
| US20040229839A1 (en) | 2003-05-14 | 2004-11-18 | Biocryst Pharmaceuticals, Inc. | Substituted nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases |
| WO2005020885A2 (en) | 2003-05-21 | 2005-03-10 | Isis Pharmaceuticals, Inc. | Compositions and methods for the treatment of severe acute respiratory syndrome (sars) |
| WO2007139946A2 (en) | 2006-05-25 | 2007-12-06 | University Of Tennessee Research Foundation | Gpcr ligands identified by computational modeling |
| DE102007001370A1 (de) | 2007-01-09 | 2008-07-10 | Curevac Gmbh | RNA-kodierte Antikörper |
| WO2009127230A1 (en) | 2008-04-16 | 2009-10-22 | Curevac Gmbh | MODIFIED (m)RNA FOR SUPPRESSING OR AVOIDING AN IMMUNOSTIMULATORY RESPONSE AND IMMUNOSUPPRESSIVE COMPOSITION |
| US20090274686A1 (en) | 2008-05-02 | 2009-11-05 | Yat Sun Or | Nucleoside phosphonate derivatives |
| EP3134411B1 (en) * | 2014-04-25 | 2021-06-30 | Boehringer Ingelheim International GmbH | Purine derivatives as cd73 inhibitors for the treatment of cancer |
| CN104530166B (zh) | 2014-12-04 | 2016-08-24 | 陕西汉江药业集团股份有限公司 | 选择性还原4,6-共轭双烯-3-酮甾体化合物的方法 |
| EP3971210A1 (en) | 2014-12-12 | 2022-03-23 | 2seventy bio, Inc. | Composition for use in the treatment of b cell related conditions in a subject in need thereof comprisine an effector cell comrising a bcma chimeric antigen receptors |
| WO2017098421A1 (en) | 2015-12-08 | 2017-06-15 | Glaxosmithkline Intellectual Property Development Limited | Benzothiadiazine compounds |
| SG11201805506YA (en) | 2016-01-08 | 2018-07-30 | Arcus Biosciences Inc | Modulators of 5'-nucleotidase, ecto and the use thereof |
| TWI767937B (zh) | 2016-09-09 | 2022-06-21 | 美商卡利泰拉生物科技公司 | 外核苷酸酶抑制劑及其使用方法 |
| EP3518934A4 (en) * | 2016-10-03 | 2020-06-24 | Arcus Biosciences, Inc. | Inhibitors of adenosine 5'-nucleotidase |
| JP7150712B2 (ja) | 2016-11-18 | 2022-10-11 | アーカス バイオサイエンシズ インコーポレイティド | Ｃｄ７３媒介免疫抑制の阻害剤 |
| CA3047988A1 (en) | 2016-12-22 | 2018-06-28 | Antengene Therapeutics Limited | Ectonucleotidase inhibitors and methods of use thereof |
| US20200115404A1 (en) * | 2017-03-31 | 2020-04-16 | Peloton Therapeutics, Inc. | Cd73 inhibitors and uses thereof |
| WO2018208727A1 (en) | 2017-05-08 | 2018-11-15 | Eternity Bioscience Inc. | Nucleoside and nucleotide analogues as cd73 inhibitors and therapeutic uses thereof |
| WO2018208980A1 (en) | 2017-05-10 | 2018-11-15 | Oric Pharmaceuticals, Inc. | Cd73 inhibitors |
| WO2019090111A1 (en) | 2017-11-03 | 2019-05-09 | Oric Pharmaceuticals, Inc. | Cd73 inhibitors |
| WO2019129059A1 (zh) | 2017-12-29 | 2019-07-04 | 上海和誉生物医药科技有限公司 | 一种具有cd73抑制活性的膦酸衍生物、其制备方法和应用 |
| CN112423764A (zh) | 2018-04-30 | 2021-02-26 | 欧瑞克制药公司 | Cd73抑制剂 |
| WO2019232319A1 (en) * | 2018-05-31 | 2019-12-05 | Peloton Therapeutics, Inc. | Compositions and methods for inhibiting cd73 |
| MX2020013320A (es) | 2018-06-21 | 2021-02-22 | Calithera Biosciences Inc | Inhibidores de ectonucleotidasa y métodos de uso de los mismos. |
| WO2020046813A1 (en) | 2018-08-27 | 2020-03-05 | Arcus Biosciences, Inc. | Cd73 inhibitors |
| CA3143496A1 (en) | 2019-06-20 | 2020-12-24 | Antengene Therapeutics Limited | Ectonucleotidase inhibitors and methods of use thereof |
| EP3999517A4 (en) | 2019-07-16 | 2023-07-12 | Oric Pharmaceuticals, Inc. | CD73 INHIBITORS |
| IL292570B2 (en) | 2019-10-30 | 2024-04-01 | Oric Pharmaceuticals Inc | Cd73 inhibitors |
-
2020
- 2020-07-15 EP EP20841341.9A patent/EP3999517A4/en not_active Withdrawn
- 2020-07-15 WO PCT/US2020/042183 patent/WO2021011689A1/en not_active Ceased
- 2020-07-15 US US17/626,731 patent/US12544391B2/en active Active
- 2020-07-15 JP JP2022502302A patent/JP7557522B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2764548T3 (es) | Procedimientos de preparación de derivados de benzodiazepina citotóxicos | |
| RU2748731C2 (ru) | Комбинация, содержащая антагонист ep4 и ингибитор иммунных контрольных точек | |
| US6194579B1 (en) | Highly lipophilic camptothecin derivatives | |
| CN111295384A (zh) | 双环类衍生物抑制剂、其制备方法和应用 | |
| WO2020065453A1 (en) | Process of manufacture of a compound for inhibiting the activity of shp2 | |
| IL268030B2 (en) | Bicyclics as allosteric shp2 inhibitors | |
| JP2024545233A5 (enExample) | ||
| MXPA01009081A (es) | Derivados de campotecina que tienen actividad anti-tumoral. | |
| JP2021534108A5 (enExample) | ||
| JP2009534358A5 (enExample) | ||
| NZ710745A (en) | Pyrrolobenzodiazepines and conjugates thereof | |
| JP2006509842A5 (enExample) | ||
| JP2022553702A5 (enExample) | ||
| JP2023533203A5 (enExample) | ||
| JP2022539256A5 (enExample) | ||
| JP2020511547A5 (enExample) | ||
| JP2006514960A5 (enExample) | ||
| HUP0103937A2 (hu) | Izoszorbid-mononitrát-származékok és alkalmazásuk csökkentett toleranciával járó értágítószerekként | |
| KR102432263B1 (ko) | 사이클릭뎁시펩타이드의 제조 방법 | |
| JP2024523422A5 (enExample) | ||
| RU2007147346A (ru) | Новые производные 2-азетидинона в качестве ингибиторов всасывания холестерина для лечения гиперлипидемических состояний | |
| IL316674A (en) | History of Oxoindolinyl Amide for Inhibition of NLRP3 and Its Uses | |
| JP2023542065A5 (enExample) | ||
| KR960029335A (ko) | 9-치환된 2-(2-n-알콕시페닐)-푸린-6- 온 | |
| RU2007126746A (ru) | Новые производные гидантоина в качестве ингибиторов металлопротеиназ |